1 November 2021 (Monday) - ASH Update

The November issue of the ASH Clinical News arrived in my in-box today. Like so much of their stuff this was clinically (rather than technically) based, and more that a little management orientated, but it was still useful nonetheless.

The just-published November issue looks at classical hematology's modern renaissance, NCI’s National Clinical Trials Network, and more!
SpotlightClassical Hematology: A Specialty in Decline?As workforce shortages persist, this ancient art is undergoing a modern renaissance.

Pulling Back the CurtainIn this edition, Carlo Brugnara, MD, talks about working in his parents’ bakery and pasta factory during childhood and his first role in academic publishing – as editor-in-chief of the American Journal of Hematology.


Editor’s Corner: Joe’s Career HacksJoseph R. Mikhael, MD, MEd, shares a dozen lessons he has learned over the last 20 years, each represented by a famous movie quote.

APs Take the Lead in Achieving Programmatic Goals: Part TwoFour advanced practice leaders discuss the role of APs in patient experience and ensuring continuity of care.

Notes From the Hill: Reflections on the FellowshipIn his final column, 2020-2021 ASH Congressional Fellow Jerome Seid, MD, reflects on the past year spent working in the office of Nevada Senator Jacky Rosen.


ASH DirectionsASH releases clinical practice guidelines on stem cell transplantation in SCD and honors Donna S. Neuberg, ScD, with the 2021 Exemplary Service Award.

The Society PagesRemembering Elihu "Eli" Estey, Thomas Waldmann, and more.

Latest & GreatestFDA grants accelerated approval to zanubrutinib for marginal zone lymphoma, grants priority review status to voxelotor for children with sickle cell disease, and more.

From the Blood Journals
Literature ScanResearch from other top journals, including:

You Make the CallThis month, Allyson Pishko, MD, MSCE, discusses management of residual vein thrombosis in a patient with a history of DVT.

Practice Update: The Evolution of NCI’s National Clinical Trials NetworkStakeholders and researchers say it is time for another critical look at the NCTN’s structure to ensure it continues to achieve its goals of facilitating innovative research and reining in bureaucracy.


No comments:

Post a Comment